Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase

• Published in: Antiviral research 2023-10, Vol.218, p.105716-105716, Article 105716
• Main Authors: Bennett, Ryan P., Yoluç, Yasemin, Salter, Jason D., Ripp, Alexander, Jessen, Henning J., Kaiser, Stefanie M., Smith, Harold C.
• Format: Article
• Language: English
• Subjects: Incorporation; Nucleoside; Polymerase; Sangivamycin; SARS-CoV-2
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2023.105716

Sangivamycin (S) is an adenosine (A) nucleoside analog with low nanomolar antiviral activity against SARS-CoV-2 in vitro. Previously, low nanomolar antiviral efficacy was revealed when tested against multiple viral variants in several cell types. SARS-CoV-2 RNA isolated from live virus infected cells and the virions released from these cells was analyzed by mass spectrometry (MS) for S incorporation. Dose-dependent incorporation occurred up to 1.8 S per 1,000 nucleotides (49 S per genome) throughout the viral genomes isolated from both infected cells and viral particles, but this incorporation did not change the viral mutation rate. In contrast, host mRNA, affinity purified from the same infected and treated cells, contained little or no S. Sangivamycin triphosphate (STP) was synthesized to evaluate its incorporation into RNA by recombinant SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) under defined in vitro conditions. SARS-CoV-2 RdRp showed that S was not a chain terminator and S containing oligonucleotides templated as A. Though the antiviral mechanism remains to be determined, the data suggests that SARS-CoV-2 RdRp incorporates STP into SARS-CoV-2 RNA, which does not significantly impair viral RNA synthesis or the mutation rate. [Display omitted] •Sangivamycin is an antiviral nucleoside analog preferentially incorporated into SARS-CoV-2 RNA by the viral polymerase.•Sangivamycin templates as an A and is not a chain terminator or a viral mutator.•Viral genomes containing sangivamycin are packaged into virions.